Drug Discovery World

APRIL 5, 2023

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. Surprisingly, the majority of the targets for drugs in early-stage development are not included in the top 10 late-stage drug targets, highlighting a shift in the targets for regenerative medicines.

Medicine 52

Medicine Gene Therapy Drugs Gene 52

XTalks

AUGUST 2, 2023

Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases that require medical interventions. Tune into this episode to learn more about YCANTH and its approval, as well as the changing landscape of dermatology, from Dr. Eichenfield.

Life Science 52

Life Science FDA Approval Dermatology Pharmacy 52

Drug Discovery World

FEBRUARY 16, 2024

This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo. News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer.

Dermatology 52

Dermatology Drugs Gene Expression Antibody 52

Pharmaceutical Technology

APRIL 19, 2023

“If approved, roflumilast foam would be the first topical drug with a new mechanism of action for this condition in over two decades, highlighting the unique formulation and deep dermatological expertise that Arcutis brings to immuno-dermatology.” in patients with seborrheic dermatitis.

Dermatology 130

Dermatology Trials Drugs Regulation 130

Pharma Mirror

MARCH 27, 2022

BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Patients seek medicines that provide effective and well tolerated. The post Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies appeared first on Pharma Mirror Magazine.

Dermatology 130

Dermatology Medicine 130

The Pharma Data

MAY 15, 2023

Positive data from two Phase 3 Dupixent ® (dupilumab) trials in prurigo nodularis published in Nature Medicine Positive results from two Phase 3 Dupixent ® (dupilumab) trials in adults with uncontrolled prurigo nodularis have been published in Nature Medicine. Gil Yosipovitch, M.D. There are about 75,000 and 70,000 adults in the U.S.

Medicine 40

Medicine Trials Dermatology FDA Approval 40

The Pharma Data

OCTOBER 29, 2020

Data support baricitinib’s ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA). . The data underscore Lilly’s commitment to providing medicines for dermatologic diseases that have high unmet need, including alopecia areata (AA). INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

Pharmaceutical Technology

MAY 19, 2023

The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology. A maintenance study showed the same effects at 52 weeks. Clinical response was observed after just two weeks in some cases.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

XTalks

APRIL 17, 2023

These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

Pharmaceutical Technology

FEBRUARY 28, 2023

It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

APRIL 17, 2023

QPS is preparing the pre-investigational new drug applications to be submitted to the US Food and Drug Administration (FDA) and the EU’s European Medicines Agency (EMA) for the CannQuit and ReneCann products. French company Eurofins Scientific is currently developing and manufacturing both products.

Dermatology 130

Dermatology Clinical Trials Clinical Trials Production 130

The Pharma Data

JUNE 2, 2023

Zouboulis, President of the European Hidradenitis Suppurativa Foundation, Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany.

Dermatology 52

Dermatology Medicine Production Marketing 52

Pharma in Brief

JULY 7, 2020

The Patented Medicine Prices Review Board ( PMPRB or Board ) has found that a patent can pertain to a medicine based on clinical similarities to the invention—even if the patent does not actually encompass the medicine. 2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders.

Medicine 40

Medicine Dermatology Containment Production 40

The Pharma Data

OCTOBER 1, 2021

The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.

Dermatology 52

Dermatology Trials Clinical Development Research 52

Pharma in Brief

JANUARY 15, 2024

The Federal Court ( FC ) has refused to overturn a decision of the Patented Medicine Prices Review Board ( PMPRB or Board ) that found that a patent can pertain to a medicine based on “clinical similarities” to the invention—even if the patent does not actually encompass the medicine. The patentee, Galderma Canada Inc.

Dermatology 52

Dermatology Medicine Containment Production 52

Drug Discovery World

SEPTEMBER 13, 2022

“Sotyktu has the potential to become the new standard of care oral treatment for people with moderate-to-severe plaque psoriasis,” said April Armstrong, MD, MPH, clinical investigator in the POETYK PSO-1 trial and Associate Dean and Professor of Dermatology at the University of Southern California.

FDA Approval 52

FDA Approval Dermatology Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

XTalks

MAY 26, 2023

Results of the trials are published in the journals Nature Medicine and The New England Journal of Medicine. Peter Marinkovich, primary investigator of the GEM-3 trial, director of the Blistering Disease Clinic at Stanford Health Care and associate professor of dermatology at the Stanford University School of Medicine.

Gene Therapy 97

Gene Therapy Gene FDA Approval Dermatology 97

pharmaphorum

SEPTEMBER 8, 2022

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). . It is hoped today’s event will serve as a “blueprint for the broader development and deployment of digital endpoints in medical product development”.

Dermatology 52

Dermatology Production Radiology Development 52

The Pharma Data

NOVEMBER 29, 2021

Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process. The FDA has assigned a Tradition Medicine Stoner Figure Act (PDUFA) thing date of September 10, 2022.

Medicine 52

Medicine Drugs Dermatology Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Its investigational medicinal products comprise R-107, R-131 and R-147. Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Its investigational medicinal products comprise R-107, R-131 and R-147. Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Drug Discovery World

FEBRUARY 16, 2024

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy.

Dermatology 64

Dermatology Licensing Licensing Medicine 64

Scienmag

JANUARY 25, 2021

Researchers at the George Washington University found that the majority of dermatology patients were comfortable with virtual visits as an alternative to in-person appointments WASHINGTON (Jan.

Dermatology 40

Dermatology Research Medicine 40

Drug Discovery World

DECEMBER 19, 2022

A double-blind, placebo-controlled clinical trial of a gene therapy gel developed at Stanford Medicine shows improved wound healing in 31 people with the disease, including 19 who were 18 years old or younger. . The results of the trial, which was funded by Krystal Biotech, were published in The New England Journal of Medicine.

Gene Therapy 52

Gene Therapy Gene Dermatology Clinical Trials 52

The Pharma Data

MAY 1, 2023

. “The fluctuating symptoms and unpredictable nature of atopic dermatitis, along with limited medicines that can adequately manage long-term uncontrolled symptoms, represent major challenges in the treatment of this chronic disease,” said Jenny Murase, M.D., P-LLY Source link: [link]

Dermatology 40

Dermatology Medicine Clinical Trials Clinical Trials 40

Drug Discovery World

MARCH 13, 2024

“Data from the FRONTIER 2 study showed that the skin clearance as seen by PASI 75 and higher-bar PASI 90 and 100 responses at 16 weeks was maintained at 52 weeks with no new safety signals across all JNJ-2113 treatment groups,” said Dr Laura Ferris, Professor of Dermatology, University of Pittsburgh.

Trials 52

Trials Dermatology Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 3, 2021

He also spent three years before that as Teva’s head of speciality medicines for Europe, and held previous senior roles at AstraZeneca, GSK and Eli Lilly. “Mr For the last three years he has served as executive vice president, growth markets commercial, at Israeli pharma Teva.

Dermatology 52

Dermatology Marketing Branding Medicine 52

FDA Law Blog

OCTOBER 10, 2023

Dr. Beitz earned a Bachelor of Arts (summa cum laude and honors in chemistry) from Barnard College, Columbia University, and a Doctor of Medicine from the College of Physicians and Surgeons, Columbia University.

Drugs 49

Drugs Dermatology Production Allergies 49

pharmaphorum

FEBRUARY 12, 2024

Medicxi has combined six biotechs with dermatology medicines in development in a single drugmaker, called Alys Pharma, which starts life with $100 million in financing.

Dermatology 125

Dermatology Medicine Development 125

Scienmag

OCTOBER 28, 2020

Analysis of the largest registry of COVID-19 patients with dermatological symptoms has revealed a subset of patients, called ‘long-haulers’ or ‘long […].

Dermatology 54

Dermatology Medicine 54

STAT News

DECEMBER 2, 2022

Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Dermatology 98

Scienmag

OCTOBER 19, 2020

One third of the cytotoxic killer cells in the liver as a potential therapeutic target Credit: MedUni Wien/Matern (Vienna, 19 October 2020) Good news for the human immune system: researchers from MedUni Vienna’s Departments of Dermatology and Surgery have managed to ascribe an immunological memory function to a subset of cytotoxic NK cells, which (..)

Dermatology 61

Dermatology Research Allergies Medicine 61

Drug Discovery World

FEBRUARY 5, 2024

Williams discussed the advantages of the company’s ‘disease agnostic’ small molecule degraders, and its success so far in translating results from preclinical to clinical tests in dermatology, inflammation and oncology indications. Product launches More than 400 exhibitors are at the event this year, many of whom are launching new products.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

Scienmag

MAY 6, 2021

More than two-thirds of the public may now have hand dermatitis due to stringent hand washing and using alcohol-based rubs during the COVID-19 pandemic LUGANO, 6 May, 2021- The dermatological impact of COVID-19 is a burning topic at EADV’s 2021 Spring Symposium.

Dermatology 40

Dermatology Research Medicine 40